Mechanisms of Refractory Hypertension (Carvedilol)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02357004|
Recruitment Status : Active, not recruiting
First Posted : February 6, 2015
Last Update Posted : September 11, 2018
|Condition or disease||Intervention/treatment||Phase|
|Hypertensive||Drug: Carvedilol Drug: Chlorthalidone||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Study Start Date :||February 2015|
|Estimated Primary Completion Date :||January 2019|
|Estimated Study Completion Date :||January 2019|
Carvedilol CR 40 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to carvedilol CR 80 mg daily (subjects will take 2 of the study pills).
CR 40 mg daily in addition to normal BP medications
Chlorthalidone 12.5 mg daily in addition to their normal BP medications. Subjects will be seen in follow-up at 2-week intervals for the duration of the 8-week intervention period. If the clinic BP remains elevated (>140/90 mmHg) at any of the follow-up visits, the study medication will be titrated up to chlorthalidone 25 mg daily (subjects will take 2 of the study pills).
12.5 mg daily in addition to normal BP medications
- % of subjects who achieve BP control (<140/90 mm Hg) [ Time Frame: 8 weeks after baseline ]BP will be measured 8 weeks after starting carvedilol and after starting chlorthaidone. The percent of subjects with BP of <140/90 mm HG in each group will be reported.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02357004
|United States, Alabama|
|David A. Calhoun, MD|
|Birmingham, Alabama, United States, 35294|
|Principal Investigator:||David A. Calhoun, MD||Cardiology Department - University of Alabama at Birmingham|